Neoleukin Therapeutics, Inc. (NLTX) Q2 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, and thank you for joining us today for the Neoleukin Therapeutics conference call. At this time, all participants are in a listen-only mode. Following the conclusion of the prepared remarks, we will conduct a question and answer session, and instructions will follow at that time. As a reminder, today's conference is being recorded. I would now like to turn the call over to Julie Rathbun, Communications for Neoleukin Therapeutics. Julie, please go ahead. Thank you. Good afternoon and welcome to Neoleucin Therapeutics' second quarter 2020-20 conference call. Joining me on the call today from Neoleucin are Jonathan Drachman, CEO, Priti Patel, Chief Medical Officer, and Sean Smith, Vice President, Finance. Today's call is being recorded. It will be available for replay on the investor relations section of the Neoleucin website approximately two hours after the call for at least 30 days. Before we start, I'd like to remind you that today's call will include forward-looking statements based on current expectations. Such statements represent management's judgments, intentions, beliefs, and expectations about future events, strategies, product candidates, and operating plans. All forward-looking statements included in this presentation are made as of today and involve assumptions, risks, and uncertainties. And actual results could differ materially from those anticipated in the forward-looking statements. Neolucan undertakes no obligation to update or revise any forward-looking statements. Please refer to the company's filings with the SEC, which are available from the SEC, or on the Neolucan website for information concerning the risk factors that could affect the company. I'll now like to turn the call over to Jonathan Drachman. Thank you, Julie, and good a...